Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies-Reference-Cited by-同舟云学术

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

Published:2019-09 Issue: Volume:135 Page:188-195
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Nosaki Kaname,Saka Hideo,Hosomi Yukio,Baas Paul^ORCID,de Castro Gilberto,Reck Martin,Wu Yi-Long^ORCID,Brahmer Julie R.,Felip Enriqueta,Sawada Takeshi,Noguchi Kazuo,Han Shi Rong,Piperdi Bilal,Kush Debra A.,Lopes Gilberto

Funder

Merck Sharp & Dohme Corp.

Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. World Cancer Report 2014;World Health Organization,2014

2. Characteristics and prognosis of Japanese male and female lung cancer patients: the BioBank Japan Project;Nakamura;J. Epidemiol.,2017

3. Cancer Statistics in Japan;Foundation for Promotion of Cancer Research,2017

4. SEER Cancer Statistics Review, 1975–2015;Noone,2018

5. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration;Talarico;J. Clin. Oncol.,2004

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;CLIN LUNG CANCER;2024

3. 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC;Clinical Lung Cancer;2024-09

4. Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database;Journal of Geriatric Oncology;2024-09

5. Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma;European Journal of Cancer;2024-08